About this company
Rea developed the first at-home diagnostic test that tracks biochemical markers of preterm birth (PTB). Our solution allows doctors to continuously follow up pregnant women at risk of PTB to anticipate a potential early delivery. Today, all of the medical examinations to monitor the risk of a PTB require invasive inspections of pregnant women. These tests have to be performed by a medical professional in a hospital, limiting significantly the number of pregnant women that can be tested. Our technology could enable obstetricians to provide personalized prophylactic treatments to decrease neonatal mortalities and morbidities. PTB is the leading cause of death among children <5 years of age &, every year, an estimated 15 million babies are born preterm.
Where you’ll find them
Open roles1
All roles at Rea Diagnostics →
